Kenneth Izuora, MD
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1023167525
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 109 payments — averaging $53.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$823
- AstraZeneca$739
- Novo Nordisk$524
- Corcept Therapeutics$377
- Insulet Corporation$299
- Medtronic$223
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,879100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 14 | $823 |
| AstraZeneca(2 entities) | 9 | $739 |
| Novo Nordisk | 10 | $524 |
| Corcept Therapeutics | 3 | $377 |
| Insulet Corporation | 5 | $299 |
| Medtronic | 5 | $223 |
| Xeris Pharmaceuticals, Inc. | 3 | $211 |
| Amryt Pharma Holdings Ltd | 3 | $181 |
| Abbott | 8 | $179 |
| Boehringer Ingelheim | 8 | $169 |
| Sanofi-aventis U.S. LLC | 3 | $141 |
| AbbVie | 2 | $139 |
| Neurocrine Biosciences, Inc. | 1 | $138 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $125 |
| Chiesi USA, Inc. | 1 | $125 |
| Gilead | 1 | $124 |
| Averitas Pharma Inc. | 1 | $119 |
| Ipsen Biopharmaceuticals, Inc | 1 | $117 |
| Bayer | 2 | $116 |
| Tandem Diabetes Care, Inc. | 1 | $114 |
| Merck | 1 | $109 |
| Esperion Therapeutics, Inc. | 1 | $109 |
| Radius Health, Inc. | 3 | $95 |
| Dexcom, Inc. | 4 | $77 |
| UCB, Inc. | 4 | $77 |
| Lilly USA, LLC | 3 | $70 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Mannkind Corporation | 2 | $42 |
| Sarepta Therapeutics, Inc. | 1 | $29 |
| Soleno Therapeutics, Inc. | 1 | $27 |
| Pfizer | 1 | $24 |
| IBSA Pharma Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$377
- MYCAPSSA$269
- Repatha$239
- EVENITY$236
- Ozempic$233
- RECORLEV$164
- MINIMED 780G$140
- CRENESSITY$138
- Yorvipath$125
- RESMETIROM$125
- FARXIGA$125
- TEPEZZA$124
- Omnipod$120
- Qutenza$119
- SOMATULINE DEPOT$117
- t:slim X2 insulin pump$114
- STEGLATRO$109
- NEXLETOL$109
How this compares
$5,879 in reported general payments places this provider in the 55th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 198 | $345,610 |
| TrulicityDulaglutide | 67 | $95,734 |
| JardianceEmpagliflozin | 64 | $66,584 |
| MounjaroTirzepatide | 42 | $43,427 |
| ProliaDenosumab | 15 | $25,684 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $22,140 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $17,165 |
| FarxigaDapagliflozin Propanediol | 16 | $15,066 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $10,312 |
| JanuviaSitagliptin Phosphate | 11 | $10,249 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $9,605 |
| TradjentaLinagliptin | 11 | $7,901 |
| NovologInsulin Aspart | 19 | $6,620 |
| Novolog FlexpenInsulin Aspart | 14 | $3,271 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 38 | $2,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $524 | $352,230217 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $70 | $139,161109 claims |
| Boehringer IngelheimJardiance, Tradjenta | $169 | $74,48475 claims |
| AmgenProlia | $823 | $25,68415 claims |
| AstraZenecaFarxiga | $739 | $15,06616 claims |
| MerckJanuvia | $109 | $10,24911 claims |
| AbbVieSynthroid | $139 | $93918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.